Citations

Clear

2509 citation(s) found for "Yang, Fu".

Endoscopic submucosal dissection vs. endoscopic mucosal resection for early Barrett's neoplasia in the West: a retrospective study
Pérez, Lady Katherine Mejía , Draganov, Peter V. , Jawaid, Salmaan , Chak, Amitabh , Dumot, John A. , Alaber, Omar , Jang, Sunguk , Mehta, Neal , Chua, Tiffany , Gabr, Moamen , Kudaravalli, Praneeth , Aihara, Hiroyuki , Ngamruengphong, Saowanee , Khoshknab, Milad Pourmousavi, Bhatt, Amit , Mejia Perez, Lady Katherine , Alaber, Omar , Fukami, Norio , Maluf-Filho, Fauze , Bhatt, Amit , Yang, Dennis J. , Vargo, John Joseph , Fukami, Norio

Mayo Clinic

Endoscopy | August 27, 2021 | Volume: 54 | Issue: 05 | Pages: 439-446

10.1055/a-1541-7659 | PMID 34450667 Get It

Abstract Background The difference in clinical outcomes after endoscopic submucosal dissection (ESD) and endoscopic mucosal resection (EMR) for early Barrett's esophagus (BE) neoplasia remains unclear. We compared the recurrence/residual tissue rates, resection outcomes, and adverse events after ESD and EMR for early BE neoplasia. Methods We included patients who underwent EMR or ESD for BE-associated high grade dysplasia (HGD) or T1a esophageal adenocarcinoma (EAC) at eight academic hospitals. We compared demographic, procedural, and histologic characteristics, and follow-up data. A time-to-event analysis was performed to evaluate recurrence/residual disease and a Kaplan–Meier curve was used to compare the groups. Results 243 patients (150 EMR; 93 ESD) were included. EMR had lower en bloc (43 % vs. 89 %; P < 0.001) and R0 (56 % vs. 73 %; P = 0.01) rates than ESD. There was no difference in the rates of perforation (0.7 % vs. 0; P > 0.99), early bleeding (0.7 % vs. 1 %; P > 0.99), delayed bleeding (3.3 % vs. 2.1 %; P = 0.71), and stricture (10 % vs. 16 %; P = 0.16) between EMR and ESD. Patients with non-curative resections who underwent further therapy were excluded from the recurrence analysis. Recurrent/residual disease was 31.4 % [44/140] for EMR and 3.5 % [3/85] for ESD during a median (interquartile range) follow-up of 15.5 (6.75–30) and 8 (2–18) months, respectively. Recurrence-/residual disease-free survival was significantly higher in the ESD group. More patients required additional endoscopic resection procedures to treat recurrent/residual disease after EMR (EMR 24.2 % vs. ESD 3.5 %; P < 0.001). Conclusions ESD is safe and results in more definitive treatment of early BE neoplasia, with significantly lower recurrence/residual disease rates and less need for repeat endoscopic treatments than with EMR.
Abstract 10: MANP Activation of the Cyclic GMP/PDE2/CYP11B2 Pathway Inhibits Aldosterone In Vitro and In Vivo
Chen, Yang , Lee, Hon-chi, Burnett, John C. , Iyer, Seethalakshmi , Nikolaev, Viacheslav O. , Naro, Fabio , Pellegrini, Manuela

Mayo Clinic

Hypertension | August 27, 2021 | Volume: 78 | Issue: Suppl_1 | Pages: No page available

10.1161/hyp.78.suppl_1.10 Get It

Aldosterone is a critical driver for cardiovascular disease (CVD). We recently discovered that MANP, a novel atrial natriuretic peptide (ANP) analog, possessed more potent aldosterone inhibitory action than ANP. MANP is currently entering clinical trials for hypertension and thus understanding its aldosterone suppressing mechanism is important. The mechanism of aldosterone inhibition by natriuretic peptides (NPs) remains to be clearly defined. Conflicting results were reported on the roles of particulate guanylyl cyclase A receptor (pGC-A) and NP clearance receptor (NPRC) in aldosterone inhibition. Furthermore, the functions of protein kinase G (PKG) and phosphodiesterases (PDE) on aldosterone regulation are not clear. Herein, we investigated the molecular mechanism of aldosterone regulation in the human adrenocortical cell line H295R and in mice. We firstly showed that pGC-A mediates aldosterone inhibition. In contrast, with NPRC agonist and antagonist, we showed that NPRC did not inhibit aldosterone. Next, we confirmed that MANP inhibits aldosterone via PDE2, not PKG, with specific agonists, antagonists, siRNA silencing, and fluorescence resonance energy transfer (FRET) experiments. Specifically, MANP suppressed ANGII mediated activation of aldosterone (fold change) MANP+ANGII 3.2±0.1* vs. ANGII 3.8±0.1 (*p<0.05) with IBMX, a PDEs inhibitor and the PDE2 antagonist Bay 60-7550 reversed MANP-mediated aldosterone suppression (IBMX+MANP+ANGII 3.9±0.2 and Bay+MANP+ANGII 4.1±0.1). With PKG agonists and inhibitors, aldosterone levels were not changed. In PDE2 activity FRET studies, aldosterone control was 3.7±0.4 and with MANP 0.9±0.2* supporting PDE2 activation by MANP. Further, the inhibitory effect of PDE2 is mediated by a reduction of intracellular Ca2+ concentration (~22%). We then showed that MANP directly reduced aldosterone synthase CYP11B2 expression in vitro. Lastly, in PDE2 knockout mice (embryonic lethal), embryonic adrenal CYP11B2 expression is markedly increased (wild type: 1±0.2, KO: 2.8±0.5*). Our findings innovatively elucidate the pGC-A/cGMP/PDE2 pathway in aldosterone inhibition by MANP in vitro and in vivo. Additionally, our data also support the development of MANP as a novel ANP analog drug for CVD.
Therapeutic Underuse and Delay in Hepatocellular Carcinoma: Prevalence, Associated Factors, and Clinical Impact
Govalan, Rajalakshmi , Luu, Michael , Lauzon, Marie , Kosari, Kambiz , Ahn, Joseph , Rich, Nicole E. , Nissen, Nicholas N. , Roberts, Lewis R. , Yang, Ju Dong , Ahn, Joseph C , Yang, Ju Dong , Roberts, Lewis R , Singal, Amit G.

Mayo Clinic

Hepatology Communications | August 26, 2021 | Volume: 6 | Issue: 1 | Pages: 223-236

10.1002/hep4.1795 | PMID 34558830 Get It

Prognosis of hepatocellular carcinoma (HCC) could be affected by lack of or delayed therapy. We aimed to characterize the prevalence, correlates, and clinical impact of therapeutic underuse and delay in patients with HCC. Patients with HCC diagnosed between 2010 and 2017 were analyzed from the United States National Cancer Database. Logistic regression analysis identified factors associated with no and delayed (>90 days after diagnosis) HCC treatment. Cox proportional hazards regression with landmark analysis assessed the association between therapeutic delay and overall survival (OS), accounting for immortal time bias. Of 116,299 patients with HCC, 24.2% received no treatment and 18.4% of treated patients had delayed treatment. Older age, Black, Hispanic, lower socioeconomic status, earlier year of diagnosis, treatment at nonacademic centers, Northeast region, increased medical comorbidity, worse liver dysfunction, and higher tumor burden were associated with no treatment. Among treated patients, younger age, Hispanic, Black, treatment at academic centers, West region, earlier tumor stage, and receipt of noncurative treatment were associated with treatment delays. In multivariable Cox regression with a landmark of 150 days, patients with and without treatment delays had similar OS (adjusted hazard ratio [aHR], 1.01; 95% confidence interval [CI], 0.98‐1.04) with a median survival of 33.7 vs. 32.1 months, respectively. However, therapeutic delay was associated with worse OS in patients who had tumor, nodes, and metastases (TNM) stage 1 (aHR, 1.06; 95% CI, 1.01‐1.11) or received curative treatment (aHR, 1.12; 95% CI, 1.05‐1.18). Conclusion: One‐fourth of patients with HCC receive no therapy and one‐fifth of treated patients experience treatment delays. Both were associated with demographic, socioeconomic, and clinical characteristics of patients as well as facility type and region. The association between therapeutic delay and survival was stage and treatment dependent.
Sex-Specific Effects of Plastic Caging in Murine Viral Myocarditis
Bruno, Katelyn A. , Macomb, Logan P. , Morales-Lara, Andrea Carolina , Mathews, Jessica, Frisancho, J. Augusto, Yang, Alex Lingyun, Florio, Damian N. Di , Edenfield, Brandy , Whelan, Emily R. , Salomon, Gary R., Hill, Anneliese R., Hewa‐Rahinduwage, Chathuranga C., Scott, Ashley Jennie , Greyner, Henry, Molina, Frank, Greenaway, Merci S., Cooper, George , Fairweather, DeLisa , Morales-Lara, A Carolina, Mathews, Jessica E, Yang, Alex L, Di Florio, Damian N, Edenfield, Brandy H, Fairweather, DeLisa , Bruno, Katelyn A , Di Florio, Damian N , Cooper, George M.

Mayo Clinic

International Journal of Molecular Sciences | August 17, 2021 | Volume: 22 | Issue: 16 | Pages: 8834

10.3390/ijms22168834 | PMID 34445539 Get It

Background: Myocarditis is an inflammatory heart disease caused by viral infections that can lead to heart failure, and occurs more often in men than women. Since animal studies have shown that myocarditis is influenced by sex hormones, we hypothesized that endocrine disruptors, which interfere with natural hormones, may play a role in the progression of the disease. The human population is exposed to the endocrine disruptor bisphenol A (BPA) from plastics, such as water bottles and plastic food containers. Methods: Male and female adult BALB/c mice were housed in plastic versus glass caging, or exposed to BPA in drinking water versus control water. Myocarditis was induced with coxsackievirus B3 on day 0, and the endpoints were assessed on day 10 post infection. Results: We found that male BALB/c mice that were exposed to plastic caging had increased myocarditis due to complement activation and elevated numbers of macrophages and neutrophils, whereas females had elevated mast cell activation and fibrosis. Conclusions: These findings show that housing mice in traditional plastic caging increases viral myocarditis in males and females, but using sex-specific immune mechanisms.
Effects of Subnormothermic Regulated Hepatic Reperfusion on Mitochondrial and Transcriptomic Profiles in a Porcine Model
Kim, Joohyun , Zimmerman, Michael A. , Shin, Woo Young , Boettcher, Brent T. , Park, Jong‐In , Ali, M. Syed, Mishra, Jyotsna , Hagen, Catherine E. , McGraw, Joseph , Woehlck, Harvey J. , Lomberk, Gwen , Camara, Amadou K.S. , Stowe, David F. , Hong, Johnny C. , Lomberk, Gwen L , Hagen, Catherine E , Lee, Ju‐Seog , Ali, Muhammed, Yang, Meiying , Mathison, Angela , Urrutia, Raúl

Mayo Clinic

Annals of Surgery | August 13, 2021 | Volume: 277 | Issue: 2 | Pages: e366-e375

10.1097/sla.0000000000005156 | PMID 34387201 Get It

Objective: We sought to investigate the biological effects of pre-reperfusion treatments of the liver after warm and cold ischemic injuries in a porcine donation after circulatory death model. Summary of Background Data: Donation after circulatory death represents a severe form of liver ischemia and reperfusion injury that has a profound impact on graft function after liver transplantation. Methods: Twenty donor pig livers underwent 60 minutes of in situ warm ischemia after circulatory arrest and 120 minutes of cold static preservation prior to simulated transplantation using an ex vivo perfusion machine. Four reperfusion treatments were compared: Control-Normothermic (N), Control- Subnormothermic (S), regulated hepatic reperfusion (RHR)-N, and RHR-S (n = 5 each). The biochemical, metabolic, and transcriptomic profiles, as well as mitochondrial function were analyzed. Results: Compared to the other groups, RHR-S treated group showed significantly lower post-reperfusion aspartate aminotransferase levels in the reperfusion effluent and histologic findings of hepatocyte viability and lesser degree of congestion and necrosis. RHR-S resulted in a significantly higher mitochondrial respiratory control index and calcium retention capacity. Transcriptomic profile analysis showed that treatment with RHR-S activated cell survival and viability, cellular homeostasis as well as other biological functions involved in tissue repair such as cytoskeleton or cytoplasm organization, cell migration, transcription, and microtubule dynamics. Furthermore, RHR-S inhibited organismal death, morbidity and mortality, necrosis, and apoptosis. Conclusion: Subnormothermic RHR mitigates IRI and preserves hepatic mitochondrial function after warm and cold hepatic ischemia. This organ resuscitative therapy may also trigger the activation of protective genes against IRI. Sub- normothermic RHR has potential applicability to clinical liver transplantation.
Current Trends and Controversies in the Management of Warthin Tumor of the Parotid Gland
Quer, Miquel , Hernandez‐Prera, Juan C. , Silver, Carl E., Casasayas, María , Simó, Ricard , Poorten, Vincent Vander , Guntinas‐Lichius, Orlando , Bradley, Patrick J. , Ng, Wai Tong , Rodrigo, Juan P. , Mäkitie, Antti , Rinaldo, Alessandra , Kowalski, Luiz Paulo , Sanabria, Álvaro , Bree, Remco de , Takes, Robert P. , López, Fernando , Olsen, Kerry D., Shaha, Ashok R. , Ferlito, Alfio , Tong-Ng, Wai , Mäkitie, Antti A , de Bree, Remco , Rodrigo, Juan P , Kowalski, Luiz P , Vander Poorten, Vincent , Sanabria, Alvaro

Mayo Clinic

Diagnostics | August 13, 2021 | Volume: 11 | Issue: 8 | Pages: 1467

10.3390/diagnostics11081467 | PMID 34441400 Get It

Purpose: To review the current options in the management of Warthin tumors (WTs) and to propose a working management protocol. Methods: A systematic literature search was conducted using PubMed and ScienceDirect database. A total of 141 publications were selected and have been included in this review. Publications were selected based on relevance, scientific evidence, and actuality. Results: The importance of parotid WTs is increasing due to its rising incidence in many countries, becoming the most frequently encountered benign parotid tumor in certain parts of the world. In the past, all WTs were treated with surgery, but because of their slow growth rate, often minimal clinical symptoms, and the advanced age of many patients, active observation has gradually become more widely used. In order to decide on active surveillance, the diagnosis of WT must be reliable, and clinical, imaging, and cytological data should be concordant. There are four clear indications for upfront surgery: uncertain diagnosis; cosmetic problems; clinical complaints, such as pain, ulceration, or recurrent infection; and the patient’s wish to have the tumor removed. In the remaining cases, surgery can be elective. Active surveillance is often suggested as the first approach, with surgery being considered if the tumor progresses and/or causes clinical complaints. The extent of surgery is another controversial topic, and the current trend is to minimize the resection using partial parotidectomies and extracapsular dissections when possible. Recently, non-surgical options such as microwave ablation, radiofrequency ablation, and ultrasound-guided ethanol sclerotherapy have been proposed for selected cases. Conclusions: The management of WT is gradually shifting from superficial or total parotidectomy to more conservative approaches, with more limited resections, and to active surveillance in an increasing number of patients. Additionally, non-surgical treatments are emerging, but their role needs to be defined in future studies.
Multimodal platform for assessing drug distribution and response in clinical trials
Lopez, Begoña G C, Kohale, Ishwar N. , Du, Ziming , Korsunsky, Ilya , Dai, Yang , Gaglia, Giorgio , Randall, Elizabeth C., Clark, Amanda R. , Marin, Bianca M. , Mladek, Ann C. , Agar, Jeffrey N. , Supko, Jeffrey G. , Wen, Patrick Y. , Lee, Eudocia Q. , Agar, Nathalie Y.R. , Marin, Bianca-Maria, Burgenske, Danielle M. , Grossman, Stuart A , Santagata, Sandro , Sarkaria, Jann, Agar, Nathalie Y R , Marin, Bianca M , Mladek, Ann C , Lopez, Begoña G C, Abdelmoula, Walid M. , Stopka, Sylwia A. , Regan, Michael S. , Basu, Sankha S. , Grossman, Stuart A. , Nabors, Burt , Raychaudhuri, Soumya , Ligon, Keith L , Wen, Patrick Yung , Alexander, Brian M. , Sarkaria, Jann N. , White, Forest M.

Mayo Clinic

Neuro-Oncology | August 11, 2021 | Volume: 24 | Issue: 1 | Pages: 64-77

10.1093/neuonc/noab197 | PMID 34383057 Get It

Abstract Background Response to targeted therapy varies between patients for largely unknown reasons. Here, we developed and applied an integrative platform using mass spectrometry imaging (MSI), phosphoproteomics, and multiplexed tissue imaging for mapping drug distribution, target engagement, and adaptive response to gain insights into heterogeneous response to therapy. Methods Patient-derived xenograft (PDX) lines of glioblastoma were treated with adavosertib, a Wee1 inhibitor, and tissue drug distribution was measured with MALDI-MSI. Phosphoproteomics was measured in the same tumors to identify biomarkers of drug target engagement and cellular adaptive response. Multiplexed tissue imaging was performed on sister sections to evaluate spatial co-localization of drug and cellular response. The integrated platform was then applied on clinical specimens from glioblastoma patients enrolled in the phase 1 clinical trial. Results PDX tumors exposed to different doses of adavosertib revealed intra- and inter-tumoral heterogeneity of drug distribution and integration of the heterogeneous drug distribution with phosphoproteomics and multiplexed tissue imaging revealed new markers of molecular response to adavosertib. Analysis of paired clinical specimens from patients enrolled in the phase 1 clinical trial informed the translational potential of the identified biomarkers in studying patient’s response to adavosertib. Conclusions The multimodal platform identified a signature of drug efficacy and patient-specific adaptive responses applicable to preclinical and clinical drug development. The information generated by the approach may inform mechanisms of success and failure in future early phase clinical trials, providing information for optimizing clinical trial design and guiding future application into clinical practice.
Editorial: when to start carvedilol in cirrhosis—time to reconsider? Authors' reply
Wijarnpreecha, Karn , Tao, Cui , Taner, C. Burcin , Tao, Cui , Wijarnpreecha, Karn , Fang, Li , Yang, Liu

Mayo Clinic

Alimentary Pharmacology & Therapeutics | August 11, 2021 | Volume: 54 | Issue: 5 | Pages: 728-729

10.1111/apt.16526 | PMID 34379839 Get It

LINKED CONTENTThis article is linked to Wijarnpreecha et al and Gillespie & Hayes papers. To view these articles, visit https://doi.org/10.1111/apt.16490 and https://doi.org/10.1111/apt.16512
Prevalence, Causes, and Health Care Burden of Pleural Effusions Among Hospitalized Adults in China
Tian, Panwen , Qiu, Rong , Xu, Shufeng , Wang, Meifang , Cao, Liming , Yang, Ping , Li, Weimin

Mayo Clinic

JAMA Network Open | August 10, 2021 | Volume: 4 | Issue: 8 | Pages: e2120306

10.1001/jamanetworkopen.2021.20306 | PMID 34374774 Get It

Extracting social determinants of health from electronic health records using natural language processing: a systematic review
Patra, Braja Gopal , Sharma, Mohit , Vekaria, Veer , Adekkanattu, Prakash , Patterson, Olga V. , Glicksberg, Benjamin S. , Ryu, Euijung , Furmanchuk, Al’ona , George, Thomas J. , Yang, Xi , Bian, Jiang , Wickramaratne, Priya , Weiner, Mark G. , Pathak, Jyotishman , Patra, Braja G , Sharma, Mohit M , Glicksberg, Benjamin , George, Thomas J , Hogan, William , Bian, Jiang , Campion, Thomas R , Weiner, Mark , Pathak, Jyotishman , Vekaria, Veer , Lepow, Lauren , Biernacka, Joanna M. , Hogan, William R. , Wu, Yonghui , Weissman, Myrna M. , Mann, J. John , Olfson, Mark

Mayo Clinic

Journal of the American Medical Informatics Association | August 5, 2021 | Volume: 28 | Issue: 12 | Pages: 2716-2727

10.1093/jamia/ocab170 | PMID 34613399 Get It

Abstract Objective Social determinants of health (SDoH) are nonclinical dispositions that impact patient health risks and clinical outcomes. Leveraging SDoH in clinical decision-making can potentially improve diagnosis, treatment planning, and patient outcomes. Despite increased interest in capturing SDoH in electronic health records (EHRs), such information is typically locked in unstructured clinical notes. Natural language processing (NLP) is the key technology to extract SDoH information from clinical text and expand its utility in patient care and research. This article presents a systematic review of the state-of-the-art NLP approaches and tools that focus on identifying and extracting SDoH data from unstructured clinical text in EHRs. Materials and Methods A broad literature search was conducted in February 2021 using 3 scholarly databases (ACL Anthology, PubMed, and Scopus) following Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. A total of 6402 publications were initially identified, and after applying the study inclusion criteria, 82 publications were selected for the final review. Results Smoking status (n = 27), substance use (n = 21), homelessness (n = 20), and alcohol use (n = 15) are the most frequently studied SDoH categories. Homelessness (n = 7) and other less-studied SDoH (eg, education, financial problems, social isolation and support, family problems) are mostly identified using rule-based approaches. In contrast, machine learning approaches are popular for identifying smoking status (n = 13), substance use (n = 9), and alcohol use (n = 9). Conclusion NLP offers significant potential to extract SDoH data from narrative clinical notes, which in turn can aid in the development of screening tools, risk prediction models, and clinical decision support systems.